Nasty Day, Nasty Month, Nasty News: Cliches Rule
All major indices and sectors sold off today making it 7 bad days out of 8 and a 6.37% correction in the S&P 500 over 30 days. The NASDAQ is now down 7.94% since May 11. Remember "sell in May and go away" ? Things were not much better in biotech-land with the IBB down 5% over one month....
Biotech Stocks Go Green Except Vertex (VRTX)
The market rallied on the seventh day after six days of losses but we still have a few hours to go. The Dow is up 0.96% and the NAZ is up 0.64%.Life Science stocks are strong overall with mid-caps up 0.75%. Diagnostics and tools are the strongest sector and within the Raygent Portfolio all...
June Gloom Continues : ASCO Buzz is Off But VRUS Soars
Stocks Down for Sixth Straight Session: Biotechs still up Over 10% YTD As we wind down from ASCO news with few catalysts ahead, investors and traders will regroup and rebalance their portfolios. The NASDAQ index is down 21 pts off 0.77% and component biotech stocks in the NASDAQ-100 are...
ASCO Stock and News Update: ARIA, BMY, EXEL, XBI
Biopharmaceutical stocks got a boost today from a rally in NASDAQ stocks and some positive news on cancer drugs from ASCO. The IBB ($106.36) was up 1.6% off its YTD and all time high of $110 and a nice rally after five days of weakness.The XBI was also up 1.97%. Many biotech stocks hit their...
Random Items: CELG Investor Network, NFLX CEO Challenges Short Seller
Celgene (CELG $58.49) is off 0.93% and down 1.29% YTD in a biotech bull market. The stock is also off 20% from 2007 and 2008 highs near $75.The Company recently bought Abraxis for $3B + and presented Abraxane data in combination with other drugs at ASCO. The Company has 25 drugs in it pipeline...